December_Spotlight

The company is expanding its US manufacturing and R&D capabilities with a $1 billion investment by 2030.

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.

Cambridge Healthcare Innovations says its dry powder inhaler engine, Quattrii, can deliver large volumes of biologic and mRNA molecules in a single inhalation.

In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.

Bulk drug calculations for different types of active moieties and drugs require different calculations and labeling.

The new facility offers cleanroom packaging and high-sensitivity analytical testing.